Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study
- Authors: Sultanbaev A.V.1,2, Kolyadina I.V.3,4, Menshikov K.V.1,2, Musin S.I.1, Nasretdinov A.F.1, Sultanbaeva N.I.1, Rakhimov R.R.1, Lipatov D.O.2, Menshikova I.A.2, Izmailov A.A.1, Lipatova E.E.2
-
Affiliations:
- Republican Clinical Oncology Dispensary
- Bashkir State Medical University
- Russian Medical Academy of Continuous Professional Education
- Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
- Issue: Vol 26, No 1 (2024)
- Pages: 65-72
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/258575
- DOI: https://doi.org/10.26442/18151434.2024.1.202612
- ID: 258575
Cite item
Full Text
Abstract
Background. The combination of alpelisib with fulvestrant is the optimal targeted endocrine therapy for patients with hormone-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with mutations in the PIK3CA gene. This regimen has been shown to be highly effective in large phase II and III studies. However, randomized clinical trials cannot fully cover all possible clinical populations of pre-treated patients. Therefore, the real-world study of the efficacy and safety of the alpelisib + fulvestrant is warranted.
Aim. A retrospective analysis of the real-world efficacy and safety of alpelisib in patients with pre-treated luminal HER2- mBC.
Materials and methods. The study included 33 patients diagnosed with HR+ HER- mBC who received alpelisib in combination with fulvestrant in routine practice from 2020 to 2023. Twelve (36.4%) patients had a mutation in exon 9 of the PIK3CA gene, and 21 (63.6%) patients had a mutation in exon 20. Alpelisib was administered to pre-treated patients in different therapy lines: the median number of mBC treatment lines before alpelisib was 5 (1–8), 1 patient received alpelisib in line 1, 4 in line 2, 6 in line 3, 5 in line 4, 8 in line 5, 1 in line 6, 7 in line 7, and 1 in line 8. Patients with luminal B-type BC accounted for 72.7% (n=24). The ECOG status of 0, 1, and 2 points had 9.1%, 75.7%, and 15.2% of patients, respectively.
Results. The median overall survival was 14.0±2.5 months (95% confidence interval 9–18.9), and the median progression-free survival was 6.0±2.7 months (95% confidence interval 0.7–11.3). The prognostic factor was an interruption of drug therapy for any reason, which increased the risk of mortality. The adverse event profile was consistent with data from previous randomized trials.
Conclusion. The outcomes of therapy with alpelisib and fulvestrant show the effectiveness of this regimen in real-world settings in patients with HR+ HER2- advanced BC with a somatic mutation in the PIK3CA gene.
Full Text
##article.viewOnOriginalSite##About the authors
Alexander V. Sultanbaev
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Author for correspondence.
Email: rkodrb@yandex.ru
ORCID iD: 0000-0003-0996-5995
Cand. Sci. (Med.)
Russian Federation, Ufa; UfaIrina V. Kolyadina
Russian Medical Academy of Continuous Professional Education; Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: irinakolyadina@yandex.ru
ORCID iD: 0000-0002-1124-6802
- D. Sci. (Med.)
Russian Federation, Moscow; Moscow
Konstantin V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Email: kmenshikov80@bk.ru
ORCID iD: 0000-0003-3734-2779
Cand. Sci. (Med.), oncologist
Russian Federation, Ufa; UfaShamil I. Musin
Republican Clinical Oncology Dispensary
Email: musin_shamil@mail.ru
ORCID iD: 0000-0003-1185-977X
Cand. Sci. (Med.), Department Head
Russian Federation, UfaAinur F. Nasretdinov
Republican Clinical Oncology Dispensary
Email: rkodrb@yandex.ru
ORCID iD: 0000-0001-8340-7962
oncologist, Department Head
Russian Federation, UfaNadezda I. Sultanbaeva
Republican Clinical Oncology Dispensary
Email: nd.sultan@rambler.ru
ORCID iD: 0000-0001-5926-0446
oncologist, Republican Clinical Oncology Dispensary
Russian Federation, UfaRadmir R. Rakhimov
Republican Clinical Oncology Dispensary
Email: radmir-rr@mail.ru
ORCID iD: 0000-0002-2488-597X
Cand. Sci. (Med.), oncologist
Russian Federation, UfaDanila O. Lipatov
Bashkir State Medical University
Email: lipatov911@gmail.com
ORCID iD: 0000-0002-3193-9008
Student
Russian Federation, UfaIrina A. Menshikova
Bashkir State Medical University
Email: i-menshikova@bk.ru
ORCID iD: 0000-0002-8665-8895
Cand. Sci. (Med.), Assoc. Prof.
Russian Federation, UfaAdel A. Izmailov
Republican Clinical Oncology Dispensary
Email: izmailov75@mail.ru
ORCID iD: 0000-0002-8461-9243
D. Sci. (Med.)
Russian Federation, UfaElena E. Lipatova
Bashkir State Medical University
Email: lipatovoleg@bk.ru
ORCID iD: 0000-0003-2588-3033
Cand. Sci. (Med.), Bashkir State Medical University
Russian Federation, UfaReferences
- Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019;21(3):25. doi: 10.1007/s11912-019-0769-3
- Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0
- Колядина И.В. По следам SABCS 2022: TOP-12 исследований по распространенному раку молочной железы, которые могут изменить нашу клиническую практику. Современная онкология. 2023;25(1):46-54 [Kolyadina IV. Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review. Journal of Modern Oncology. 2023;25(1):46-54 (in Russian)]. doi: 10.26442/18151434.2023.1.202102
- Колядина И.В. Рибоциклиб в лечении больных HR+ HER2-отрицательным распространенным раком молочной железы: обновленные результаты рандомизированных клинических исследований и их роль для клинической практики. Опухоли женской репродуктивной системы. 2021;17(2):58-67 [Kolyadina IV. Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice. Tumors of Female Reproductive System. 2021;17(2):58-67 (in Russian)]. doi: 10.17650/1994-40 98-2021-17-2-58-67
- Гречухина К.С., Воронцова К.А., Куко Т.М., и др. Абемациклиб – уникальный представитель класса ингибиторов CDK4/6 в лечении HR+ HER2- метастатического рака молочной железы. Фарматека. 2021;28(7):15-27 [Grechukhina KS, Vorontsova KA, Kuko TM, et al. Abematsiklib – unikal’nyi predstavitel’ klassa ingibitorov CDK4/6 v lechenii HR+ HER2- metastaticheskogo raka molochnoi zhelezy. Farmateka. 2021;28(7):15-27 (in Russian)].
- Martínez-Sáez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45. doi: 10.1186/s13058-020-01284-9
- Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-86. doi: 10.1016/j.annonc.2019.11.006
- Sultanbaev A, Nasretdinov A, Menshikov K, et al. Abstract P1-07-09: Results of treatment with inhibitors of cycline-dependent kinase CDK4/6 in patients with breast cancer in the presence of different types mutation in the PIK3CA gene. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10. Cancer Res. 2022;82(Suppl. 4): abstract P1-07-09. doi: 10.1158/1538-7445.SABCS21-P1-07-09
- Mangone FR, Bobrovnitchaia IG, Salaorni S, et al. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo). 2012;67(11):1285-90. doi: 10.6061/clinics/2012(11)11
- André F, Ciruelos E, Rubovszky G, et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-40. doi: 10.1056/NEJMoa1813904
- Липатов О.Н., Султанбаева Н.И., Меньшиков К.В., Султанбаев А.В. Опыт определения мутаций в гене PIK3CA у больных раком молочной железы в Республике Башкортостан. Злокачественные опухоли. 2020;10(3S1):108-9 [Lipatov ON, Sultanbaeva NI, Men’shikov KV, Sultanbaev AV. Opyt opredeleniia mutatsii v gene PIK3CA u bol’nykh rakom molochnoi zhelezy v Respublike Bashkortostan. Malignant Tumours. 2020;10(3S1):108-9 (in Russian)].
- Семиглазова Т.Ю., Сорокина И.В. Прогностическое и предиктивное значения мутации гена PIK3CA у больных раком молочной железы. Фарматека. 2019;26(7):10-20 [Semiglazova TIu, Sorokina IV. Prognostic and predictive values of the PIK3CA gene mutation in patients with breast cancer. Farmateka. 2019;26(7):10-20 (in Russian)]. doi: 10.18565/pharmateca.2019.7.10-20
- Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120-8. doi: 10.1016/j.gene.2019.02.076
- Kaklamani VG, Richardson AL, Arteaga CL. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. Oncologist. 2019;24(3):305-12. doi: 10.1634/theoncologist.2018-0314
- Sobhani N, Roviello G, Corona SP, et al. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018;119(6):4287-92. doi: 10.1002/jcb.26687
- Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018;36(13):1291-9. doi: 10.1200/JCO.2017.72.7107
- Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials. Mol Cancer Ther. 2014;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865
- André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208-17. doi: 10.1016/j.annonc.2020.11.011
- Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001-10. doi: 10.1016/j.annonc.2020.05.001
- Kushi R, Hirota Y, Ogawa W. Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway. Diabetol Int. 2020;12(1):62-7. doi: 10.1007/s13340-020-00455-5
- Tankova T, Senkus E, Beloyartseva M, et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers (Basel). 2022;14(7):1598. doi: 10.3390/cancers14071598
- Шливко И.Л., Гаранина О.Е., Артамонова Е.В., и др. Консенсус по профилактике и коррекции сыпи у пациентов, получающих терапию препаратом алпелисиб. Современная Онкология. 2021;23(4):572-6 [Shlivko IL, Garanina OE, Artamonova EV, et al. The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2021;23(4):572-6 (in Russian)]. doi: 10.26442/18151434.2021.4.201275
- Chia S, Neven P, Ciruelos EM, et al. Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study. J Clin Oncol. 2023;41(Suppl. 16):1078. doi: 10.1200/JCO.2023.41.16_suppl.1078
- Тюляндин С.А., Артамонова Е.В., Жигулев А.Н., и др. Практические рекомендации по лекарственному лечению рака молочной железы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(3s2):157-200 [Tiuliandin SA, Artamonova EV, Zhigulev AN, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka molochnoi zhelezy. Prakticheskie rekomendatsii RUSSCO, chast’ 1. Malignant Tumours. 2023;13(3s2):157-200 (in Russian)].
- Turner S, Chia S, Kanakamedala H, et al. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Oncologist. 2021;26(7):e1133-42. doi: 10.1002/onco.13804
- Банов С.М., Гуторов С.Л., Колядина И.В., и др. Рак молочной железы с метастазами в головной мозг: современные возможности лечения. Вопросы онкологии. 2021;67(5):614-23 [Banov SM, Gutorov SL, Kolyadina IV, et al. Breast cancer with brain metastases: current treatment options. Voprosy onkologii. 2021;67(5):614-23 (in Russian)].
- Филоненко Д.А., Белогурова А.В., Султанбаев А.В., и др. Эффективность алпелисиба при метастазах в головном мозге люминального HER2-негативного рака молочной железы: клинические наблюдения. Вопросы онкологии. 2023;69(1):135-42 [Filonenko DA, Belogurova AV, Sultanbaev AV, et al. Alpelisib efficacy in luminal HER2-negative breast cancer with brain metastases: clinical cases. Voprosy onkologii. 2023;69(1):135-42 (in Russian)]. doi: 10.37469/0507-3758-2023-69-1–135-142